Note 15 - Segment Information

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

15. Segment Information

Tivic Health is a late-stage therapeutics company harnessing the power of the immune system to improve clinical outcomes and save lives. Tivic’s biopharma program is focused on advancing its first drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing, and filing the associated Biologics License Application with the FDA, with the intent to sell the biologic compounds either inside or outside of the United States. Tivic’s bioelectronic program has focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. Tivic has an FDA-approved over-the-counter device, ClearUP, that treats sinus pain and pressure, which it plans to discontinue before the end of the year. Historically, revenue has been derived from sales of the Company’s first commercial product, ClearUP.  To date, the Company has managed its business activities as a single operating segment. Tivic’s Chief Executive Officer is the CODM. The CODM utilizes the Company’s long-term plan, which includes product development roadmaps and long-term financial models, as key input to resource allocation. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using factors such as gross margin, operating expenses, loss from operations and net loss.

Significant expenses within loss from operations, as well as within net loss, include costs of revenue, research and development, selling and marketing and general and administrative expenses, which are each separately presented on the Company’s Statements of Operations. Other segment items within net loss include interest income and the loss from the disposal of manufacturing molds and dies. 

During the three and nine months ended September 30, 2025 and 2024, all revenue was domestic revenue. To date, the Company has not sold its product outside of the United States.

The Company’s long-lived assets consist primarily of computer equipment and the licensed biologics, all of which are located in the United States.